A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

Pfizer

Status and phase

Completed

Phase 2

Conditions

Meningococcal Vaccine

Treatments

Biological: Vaccine

Study type

Interventional

Funder types

Industry

Identifiers

NCT01299480

2009-014493-18 (EudraCT Number)

B1971012

6108A1-2003 (Other Identifier)

Details and patient eligibility

About

This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how well it is tolerated. This study will also look at this vaccine being given 2 or 3 times. This study will be done in healthy adolescents.

Enrollment

1,714 patients

Sex

All

Ages

11 to 18 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Evidence of a personally signed and dated informed consent document indicating that the parent/legally acceptable representative and/or subject has been informed of all pertinent aspects of the study.
Parent/legally acceptable representative and/or subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
Male or female subject aged ≥11 and <19 years at the time of enrollment.
Available for the entire study period and can be reached by telephone.
Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
All male and female subjects must agree to practice a form of effective contraception, such as barrier contraception (ie, condom plus spermicide, a female condom, diaphragm, cervical cap or intrauterine device), implants, injectables, combined oral contraceptives or sexual abstinence prior to entering into the study, for the duration of the vaccination period and for 28 days after the last study vaccination.For Germany: The phrase sexual abstinence is not applicable, with the understanding that all male and all female subjects of childbearing potential must practice an effective form of contraception during the study.
Negative urine pregnancy test for female subjects.

Exclusion criteria

Previous vaccination with any meningococcal serogroup B vaccine.
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
A known or suspected disease of the immune system or those receiving immunosuppressive therapy.
History of culture-proven disease caused by Neisseria meningitidis or Neisseria gonorrhoeae.
Significant neurological disorder or history of seizure (excluding simple febrile seizure).
Receipt of any blood products, including immunoglobulin within 6 months before the first study vaccination.
Current chronic use of systemic antibiotics.
Participation in other studies during study participation. Participation in purely observational studies is acceptable.
Received any investigational drugs, vaccines or devices within 28 days before administration of the first study vaccination.
Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
Subject is pregnant or breastfeeding.
Subject is a direct descendant of study site or Pfizer personnel

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

1,714 participants in 5 patient groups

Group 1

Experimental group

Description:

rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3

Treatment:

Biological: Vaccine

Group 2

Experimental group

Description:

rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2

Treatment:

Biological: Vaccine

Group 3

Experimental group

Description:

rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3

Treatment:

Biological: Vaccine

Group 4

Experimental group

Description:

rLP2086 at visits 1 and 3, saline at visits 2 and 5

Treatment:

Biological: Vaccine

Group 5

Experimental group

Description:

rLP2086 at visits 3 and 5, saline at visits 1 and 2

Treatment:

Biological: Vaccine

Trial contacts and locations

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms